collection
MENU ▼
Read by QxMD icon Read
search

Cardioncologia

shared collection
115 papers 0 to 25 followers
By Eduardo Roque Cardiologista com foco em cardiologia hospitalar e cuidados intensivos. Professor de clínica médica.
https://www.readbyqxmd.com/read/28279420/how-to-develop-a-cardio-oncology-clinic
#1
REVIEW
David Snipelisky, Jae Yoon Park, Amir Lerman, Sharon Mulvagh, Grace Lin, Naveen Pereira, Martin Rodriguez-Porcel, Hector R Villarraga, Joerg Herrmann
Cardiovascular demands to the care of cancer patients are common and important given the implications for morbidity and mortality. As a consequence, interactions with cardiovascular disease specialists have intensified to the point of the development of a new discipline termed cardio-oncology. As an additional consequence, so-called cardio-oncology clinics have emerged, in most cases staffed by cardiologists with an interest in the field. This article addresses this gap and summarizes key points in the development of a cardio-oncology clinic...
April 2017: Heart Failure Clinics
https://www.readbyqxmd.com/read/28279421/how-to-develop-a-cardio-oncology-fellowship
#2
REVIEW
Michelle N Johnson, Richard Steingart, Joseph Carver
Management of cardiovascular disease in patients with cancer and cancer survivors requires particular clinical expertise and skills that are central to cardio-oncology. The areas of knowledge required include specific cardiovascular complications directly related to oncologic therapies and the impact of cancer and its therapies on existing or potential cardiovascular comorbidities. Many cancer therapeutics have potential cardiotoxicity. The conversion of many cancers to chronic conditions, rather than fatal diseases, has produced a population of patients with cancer at high risk for cardiovascular diseases that require specialized knowledge of treating physicians...
April 2017: Heart Failure Clinics
https://www.readbyqxmd.com/read/28279424/cardio-oncology-the-role-of-big-data
#3
REVIEW
Anant Mandawat, Andrew E Williams, Sanjeev A Francis
Despite its challenges, a "big data" approach offers a unique opportunity within the field of cardio-oncology. A pharmacovigilant approach using large data sets can help characterize cardiovascular toxicities of the rapidly expanding armamentarium of targeted therapies. Creating a broad coalition of data sharing can provide insights into the incidence of cardiotoxicity and stimulate research into the underlying mechanisms. Population health necessitates the use of big data and can help inform public health interventions to prevent both cancer and cardiovascular disease...
April 2017: Heart Failure Clinics
https://www.readbyqxmd.com/read/28073142/cardio-oncology-progress-in-diagnosis-and-treatment-of-cardiac-dysfunction
#4
REVIEW
J Tromp, L C Steggink, D J Van Veldhuisen, J A Gietema, P van der Meer
No abstract text is available yet for this article.
January 10, 2017: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28029315/left-ventricular-dysfunction-with-trastuzumab-therapy-is-primary-prevention-the-best-option
#5
Paaladinesh Thavendiranathan, Eitan Amir
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice...
March 10, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27943255/self-reported-physical-activity-levels-of-older-cancer-survivors-results-from-the-2014-national-health-interview-survey
#6
Yelena Tarasenko, Chen Chen, Nancy Schoenberg
OBJECTIVES: To examine adherence to the American College of Sports Medicine and American Cancer Society guidelines on leisure-time aerobic and muscle-strengthening physical activity (PA) of older cancer survivors. DESIGN: Cross-sectional study based on the 2014 National Health Interview Survey. SETTING: United States. PARTICIPANTS: Young-old (65-74) (n = 627), old-old (≥75) (n = 656), and middle-aged (45-64) (n = 786) cancer survivors and adults without cancer (n = 18,369), stratified according to the same age groups...
December 9, 2016: Journal of the American Geriatrics Society
https://www.readbyqxmd.com/read/27629548/rationale-and-design-of-the-multidisciplinary-team-intervention-in-cardio-oncology-study-titan
#7
Edith Pituskin, Mark Haykowsky, Margaret McNeely, John Mackey, Neil Chua, Ian Paterson
BACKGROUND: Cancer is the leading cause of premature death in Canada. In the last decade, important gains in cancer survival have been achieved by advances in adjuvant treatment. However, many oncologic treatments also result in cardiovascular "toxicity". Furthermore, cardiac risk factors such as hypertension, dyslipidemia, and diabetes mellitus are known to contribute to the progression of cardiac damage and clinical cardiotoxicity. As such, for many survivors, the risk of death from cardiac disease exceeds that of recurrent cancer...
September 15, 2016: BMC Cancer
https://www.readbyqxmd.com/read/27660568/cardiovascular-risk-and-level-of-statin-use-among-women-with-breast-cancer-in-a-cardio-oncology-clinic
#8
Kelly Shum, Amber Solivan, Parham Parto, Nichole Polin, Eiman Jahangir
BACKGROUND: Because of the improvements in survival rates, patients with breast cancer are now more likely to die from cardiovascular disease than from cancer. Thus, providing appropriate preventive cardiovascular care to patients with cancer is of the utmost importance. METHODS: We retrospectively compared the cardiovascular risk and management of 146 women treated at the Cardio-Oncology (Cardio-Onc) and the Obstetrics and Gynecology (Ob-Gyn) clinics. We calculated cardiovascular risk using the American College of Cardiology (ACC)/American Heart Association (AHA) atherosclerotic cardiovascular disease (ASCVD) risk calculator and the Framingham Risk Score Calculator...
2016: Ochsner Journal
https://www.readbyqxmd.com/read/27660573/cardio-oncology-a-focused-review-of-anthracycline-human-epidermal-growth-factor-receptor-2-inhibitor-and-radiation-induced-cardiotoxicity-and-management
#9
REVIEW
Jean Domercant, Nichole Polin, Eiman Jahangir
BACKGROUND: Cardio-oncology is a collaborative approach between cardiologists and oncologists in the treatment of patients with cancer and heart disease. Radiation and chemotherapy have played a major role in the decreased cancer-related mortality achieved in the past 2 decades. However, anthracycline-, tyrosine kinase-, and radiation-based therapies are each associated with independent cardiovascular (CV) risks, and these risks are cumulative when these therapies are used in combination...
2016: Ochsner Journal
https://www.readbyqxmd.com/read/27830273/-summary-of-the-esc-position-paper-on-cancer-treatment-and-cardiovascular-toxicity
#10
J Hoog, S Achenbach
The numbers of survivors of cancer have increased as a consequence of advances in chemotherapy; however, the side effects of cancer treatment have become increasingly more important. The most frequent side effects include cardiovascular complications, which can lead to acute and delayed morbidity and mortality, often many years later. The discipline of cardio-oncology deals with the prevention, diagnostics and treatment of cardiovascular diseases caused by cancer therapy. The most important cardiovascular side effects of cytostatic therapy are heart failure due to myocardial dysfunction (cardiotoxicity), coronary artery disease, valvular disease and ventricular arrhythmia as a result of QT extension...
December 2016: Herz
https://www.readbyqxmd.com/read/27893331/multidisciplinary-approach-to-novel-therapies-in-cardio-oncology-research-manticore-101-breast-a-randomized-trial-for-the-prevention-of-trastuzumab-associated-cardiotoxicity
#11
Edith Pituskin, John R Mackey, Sheri Koshman, Davinder Jassal, Marshall Pitz, Mark J Haykowsky, Joseph J Pagano, Kelvin Chow, Richard B Thompson, Larissa J Vos, Sunita Ghosh, Gavin Y Oudit, Justin A Ezekowitz, D Ian Paterson
Purpose The primary toxicity of trastuzumab therapy for human epidermal growth factor receptor 2-overexpressing (HER2-positive) breast cancer is dose-independent cardiac dysfunction. Angiotensin-converting enzyme inhibitors and β-blockers are recommended first-line agents for heart failure. We hypothesized that angiotensin-converting enzyme inhibitors and β-blockers could prevent trastuzumab-related cardiotoxicity. Patients and Methods In this double-blinded, placebo-controlled trial, patients with HER2-positive early breast cancer were randomly assigned to receive treatment with perindopril, bisoprolol, or placebo (1:1:1) for the duration of trastuzumab adjuvant therapy...
March 10, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27903214/chemotherapy-and-cardiotoxicity-in-hematologic-malignancies-a-review
#12
Antonio Stellitano, Roberta Fedele, Santina Barillà, Antonino Iaria, Carmelo Massimiliano Rao, Massimo Martino
Antineoplastic agents affect the cardiovascular system, and the incidence of cardiotoxicity is continuously growing in patients with hematologic malignancies and treated with antineoplastic therapy. Cardio-oncology is a quite young discipline, designed for diagnosis, prevention and treatment of cardiovascular complications of anticancer agents. Nowadays, with the current treatments and an accurate pharmacological control of comorbidities present at the time of the oncological diagnosis, early clinical events are infrequent, and it seems indeed that cardiotoxicity could emerge as time and years go by, after therapies completion...
November 21, 2016: Current Cancer Drug Targets
https://www.readbyqxmd.com/read/27694539/an-esc-position-paper-on-cardio-oncology
#13
José Zamorano
No abstract text is available yet for this article.
September 21, 2016: European Heart Journal
https://www.readbyqxmd.com/read/27694540/the-evolving-field-of-cardio-oncology-beyond-anthracyclines-and-heart-failure
#14
Michael G Fradley
No abstract text is available yet for this article.
September 21, 2016: European Heart Journal
https://www.readbyqxmd.com/read/27721532/benefits-of-antihypertensive-medications-for-anthracycline-and-trastuzumab-induced-cardiotoxicity-in-patients-with-breast-cancer-insights-from-recent-clinical-trials
#15
Katarzyna Rygiel
Advances in oncologic therapies have allowed many patients with breast cancer to achieve better outcomes and longer survival. However, this progress has been tempered by cardiotoxicity, associated with anticancer therapies, ranging from subclinical abnormalities to irreversible life-threatening complications, such as congestive heart failure or cardiomyopathy. In particular, exposure to chemotherapy (CHT), including anthracyclines and trastuzumab, can lead to cardiac dysfunction with short- or long-term consequences, among patients with breast cancer...
September 2016: Indian Journal of Pharmacology
https://www.readbyqxmd.com/read/27721934/novel-concepts-in-radiation-induced-cardiovascular-disease
#16
REVIEW
Jason R Cuomo, Gyanendra K Sharma, Preston D Conger, Neal L Weintraub
Radiation-induced cardiovascular disease (RICVD) is the most common nonmalignant cause of morbidity and mortality among cancer survivors who have undergone mediastinal radiation therapy (RT). Cardiovascular complications include effusive or constrictive pericarditis, cardiomyopathy, valvular heart disease, and coronary/vascular disease. These are pathophysiologically distinct disease entities whose prevalence varies depending on the timing and extent of radiation exposure to the heart and great vessels. Although refinements in RT dosimetry and shielding will inevitably limit future cases of RICVD, the increasing number of long-term cancer survivors, including those treated with older higher-dose RT regimens, will ensure a steady flow of afflicted patients for the foreseeable future...
September 26, 2016: World Journal of Cardiology
https://www.readbyqxmd.com/read/27609196/validating-the-pharmacogenomics-of-chemotherapy-induced-cardiotoxicity-what-is-missing
#17
REVIEW
Tarek Magdy, Brian T Burmeister, Paul W Burridge
The cardiotoxicity of certain chemotherapeutic agents is now well-established, and has led to the development of the field of cardio-oncology, increased cardiac screening of cancer patients, and limitation of patients' maximum cumulative chemotherapeutic dose. The effect of chemotherapeutic regimes on the heart largely involves cardiomyocyte death, leading to cardiomyopathy and heart failure, or the induction of arrhythmias. Of these cardiotoxic drugs, those resulting in clinical cardiotoxicity can range from 8 to 26% for doxorubicin, 7-28% for trastuzumab, or 5-30% for paclitaxel...
December 2016: Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27582370/baseline-immunoglobulin-e-levels-as-a-marker-of-doxorubicin-and-trastuzumab-associated-cardiac-dysfunction
#18
Lynn A Beer, Andrew V Kossenkov, Qin Liu, Eline Luning Prak, Susan Domchek, David W Speicher, Bonnie Ky
RATIONALE: There is a critical need to develop robust, mechanistic strategies to identify patients at increased risk of cancer therapeutics-related cardiac dysfunction (CTRCD). OBJECTIVE: We aimed to discover new biomarkers associated with doxorubicin- and trastuzumab-induced CTRCD using high-throughput proteomic profiling. METHODS AND RESULTS: Plasma, echocardiograms, and clinical outcomes were collected at standardized intervals in breast cancer patients undergoing doxorubicin and trastuzumab cancer therapy...
October 28, 2016: Circulation Research
https://www.readbyqxmd.com/read/27566332/echocardiographic-assessment-of-cardiotoxic-effects-of-cancer-therapy
#19
REVIEW
Wendy J Bottinor, Christopher K Migliore, Carrie A Lenneman, Marcus F Stoddard
Patients with cancer can present with difficult management issues, as the medicine can sometimes cause sequelae destructive to healthy tissue. As this population lives longer, cardiotoxic effects are beginning to emerge, but the early recognition of this signal can prove difficult, with too late a recognition leading to lifelong cardiac impairment and dysfunction. Cardio-oncology can bridge this difficulty, and echocardiography and its newer imaging abilities are proving efficacious in this population. This article will address common sequelae of cardiotoxic treatment regimens and offer recommendations for echocardiographic surveillance...
October 2016: Current Cardiology Reports
https://www.readbyqxmd.com/read/27085030/-cardio-oncology-implications-for-interventionists
#20
EDITORIAL
James A Goldstein
CV complications in cancer patients predominantly result from collateral damage from chemotherapy and radiation Complex interplay of manifold pathophysiologic processes poses evaluation challenges and management conundrums. Pre-cath planning essential, employing advanced non-invasive imaging of myocardium, PC, and great vessels.
April 2016: Catheterization and Cardiovascular Interventions
label_collection
label_collection
4812
1
2
2016-08-23 05:49:28
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"